Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 November 2021 | Story Andrè Damons
Prof Motlalepula Matsabisa
Good news galore. Prof Motlalepula Matsabisa, Professor and Director of Pharmacology at the University of the Free State (UFS), received more good news recently when he was awarded a Visiting Professorship at the Beijing University of Chinese Medicine (BUCM) in Beijing, China, as well as being elected as the Deputy President of the South African Society for Basic and Clinical Pharmacology. Prof Matsabisa was also recommended by Dr Blade Nzimande, Minister of Higher Education, Science and Technology, part of the IBSA technical committee.

Prof Motlalepula Matsabisa, Professor and Director of Pharmacology at the University of the Free State (UFS), received more good news recently when he was awarded a Visiting Professorship at the Beijing University of Chinese Medicine (BUCM) in Beijing, China. This news comes at the same time as the traditional medicine expert has been elected as the Deputy President of the South African Society for Basic and Clinical Pharmacology.

This is, however, not the end of the good news for Prof Matsabisa. Dr Blade Nzimande, Minister of Higher Education, Science and Technology, recommended him to Naledi Pandor, Minister of International Relations and Cooperation, to be part of the India, Brazil and South Africa (IBSA) working group in traditional medicine. As a member of the Department of Science and Innovation (DSI) Indigenous Knowledge-based Bio-Innovation programme, Prof Matsabisa, together with Prof Nceba Gqaleni, is part of the IBSA technical committee. Prof Matsabisa is also part of a technical team for National Department of Health on traditional medicines for the IBSA countries 

Unexpected honours

“I was not expecting any of these honours. It comes as a total shock. To have gone through the stringent evaluation and selection process at the BUCM and made it to the university’s highest award, is an honour. This is recognition of my academic and research quality by my peers on an international level.

“Being elected to lead a society of researchers and clinicians in the field of Pharmacology in the country is further recognition nationally of the academic and research excellence status. These awards coming at the same time is unbelievable. I am proud of the work I do as well as a gesture of support from scientists nationally and internationally and the support from UFS having allowed me to do what I do best academically,” says Prof Matsabisa.

According to him, some of the key expectations for this Visiting Professorship at the BUCM are teaching, to do collaborative research and conduct workshops jointly as well as joint leverage of research funding and co-publications. Prof Matsabisa will now, together with his counterparts at BUCM, discuss and synchronise their teaching and research so they plan the visit to benefit the UFS and the BUCM.

The South African Society for Basic and Clinical Pharmacology’s main activities are to bring pharmacologists together and share new scientific knowledge and developments in the field, explains Prof Matsabisa. The Society is for teaching and training; including research in both basic and clinical pharmacology, to support pharmacology conferences nationally and continentally. “We develop young pharmacologists and are also affiliated to international pharmacology societies. The purpose of the South African Society for Basic and Clinical Pharmacology is to excel and grow the pharmacology field in medicine.”

A good year for pharmacology and the UFS

This has been a good year for him and the team, for pharmacology and the UFS, says Prof Matsabisa. Most recently, Prof Matsabisa and the Department of Pharmacology received a grant of R58 million to establish one of the most advanced modern Pharmacology GLP-accredited research and development laboratories in the country, and possibly in the region. The department has also been awarded an annual Technology and Innovation Agency Platform (TIA) grant of R17 million for the next five years early this year.

“I am able to do what I do and achieve all this because of teamwork. I have a value chain of teams from support staff, cleaners, security, technical and research scientists with me. I have good students, postdoctoral fellows as well as management behind me.

“I hope such an environment can be given to all researchers to do what they do best and be supported fully and genuinely by senior management with decisions that are favourable to growing the institution without any favouritism or prejudice to anyone. It has indeed been a good year with all the funding we received. Watch this space for more.”

Looking forward most to China

Prof Matsabisa says he is looking forward to taking some of his postgraduate students with him to spend time at BUCM for training and conducting research. Says Prof Matsabisa: “I have very good postgraduate research students that need all the support. I look forward to spending a month or so at BUCM teaching BUCM students. I will leave my students there in good hands for 6-12 months per year. I promise, when these students return, they will return with a positive attitude for research and accountability.”

This was the case for him when he got a British scholarship to spend time at GlaxoSmithKline and the University of Bradford in the UK for his PhD. 

Prof Matsabisa hopes to use this Professorship at BUCM to popularise the work of the UFS and to create opportunities for new and upcoming researchers in the field of Pharmacology of Medicinal plants. This is his development plan

News Archive

Two scientists part of team that discovers the source of the highest energy cosmic rays at the centre of the Milky Way
2016-03-22

Description: Giant molecular clouds  Tags: Giant molecular clouds

Artist's impression of the giant molecular clouds surrounding the Galactic Centre, bombarded by very high energy protons accelerated in the vicinity of the central black hole and subsequently shining in gamma rays.
Artist's impression: © Dr Mark A. Garlick/ H.E.S.S. Collaboration

Spotlight photo:
Dr Brian van Soelen and Prof Pieter Meintjes of the UFS Department of Physics.
Photo: Charl Devenish

H.E.S.S. (High Energy Stereoscopic System) scientists publically revealed their latest galactic discovery in the international science journal, Nature, on 16 March 2016. These scientists were able to pinpoint the most powerful source of cosmic radiation – which, up to now, remained a mystery.

Part of this team of scientists are Prof Pieter Meintjes and Dr Brian van Soelen, both in the University of the Free State (UFS) Department of Physics. Dr Van Soelen explains that they have discovered a proton PeVatron – a source that can accelerate protons up to energies of ~1 PeV (10^15 eV) – at the centre of the Milky Way. The supermassive black hole called Sagittarius A has been identified as the most plausible source of this unprecedented acceleration of protons.

The protons are accelerated to Very High Energy (VHE) gamma rays. The energy of these protons are 100 times larger than those achieved by the Large Hadron Collider at CERN (the European Organization for Nuclear Research).

According to Dr Van Soelen, the fact that this research has been published in Nature demonstrates the importance and pioneering nature of the research conducted by H.E.S.S. The H.E.S.S. observatory – operational in Namibia – is a collaboration between 42 scientific institutions in 12 countries.

In 2006, H.E.S.S. was awarded the Descartes Prize of the European Commission – the highest recognition for collaborative research – and in 2010 the prestigious Rossi Prize of the American Astronomical Society. The extent of the observatory’s significance places it among the ranks of the Hubble Space Telescope and the telescopes of the European Southern Observatory in Chile.

“The next generation VHE gamma-ray telescope,” Dr Van Soelen says, “will be the Cherenkov Telescope Array (CTA), which is currently in the design and development stage.” Both Dr Van Soelen and Prof Meintjes are part of this project as well.

H.E.S.S. has issued a complete statement about the paper published in Nature.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept